Congruently, exploration of scRNA-seq data (via Single Cell Portal) revealed that elevated levels of ITGAV, ITGB3 and ITGB5 in myeloid cells are negative predictors of ICI therapy response in melanoma and renal cell carcinoma patients (Fig. 6I). This evidence concerns the gene ITGB5 and hereditary clear cell renal cell carcinoma.